REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · IEX Real-Time Price · USD
21.19
+3.75 (21.50%)
At close: Mar 1, 2024, 4:00 PM
21.49
+0.30 (1.42%)
After-hours: Mar 1, 2024, 7:57 PM EST
21.50%
Market Cap 941.42M
Revenue (ttm) 90.24M
Net Income (ttm) -263.49M
Shares Out 44.43M
EPS (ttm) -6.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,508,382
Open 17.86
Previous Close 17.44
Day's Range 17.70 - 21.69
52-Week Range 11.83 - 24.51
Beta 1.20
Analysts Buy
Price Target 37.14 (+75.27%)
Earnings Date Feb 27, 2024

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenn... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2015
Employees 344
Stock Exchange NASDAQ
Ticker Symbol RGNX
Full Company Profile

Financial Performance

In 2023, REGENXBIO's revenue was $90.24 million, a decrease of -19.94% compared to the previous year's $112.72 million. Losses were -$263.49 million, -6.00% less than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price forecast is $37.14, which is an increase of 75.27% from the latest price.

Price Target
$37.14
(75.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D.

3 days ago - PRNewsWire

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Prioritized pipeline is expected to further progress to pivotal stage and firs...

5 days ago - PRNewsWire

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m.

11 days ago - PRNewsWire

Jim Cramer lists his top 10 stocks that have jumped this week

'Mad Money' host Jim Cramer looks at the stocks that have jumped this week as the bull market continues to run.

24 days ago - CNBC Television

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Results support BLA submission in 2024 using the accelerated approval pathway Primary endpoint of patients achieving reduction in CSF biomarker of MPS II disease was met with statistical significance ...

25 days ago - PRNewsWire

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a no...

25 days ago - PRNewsWire

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

Pivotal topline results from the CAMPSIITE® trial of RGX-121 for the treatment of MPS II to be presented Conference call Wednesday, February 7, 4:30 p.m. ET ROCKVILLE, Md.

4 weeks ago - PRNewsWire

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical chal...

6 weeks ago - PRNewsWire

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

ROCKVILLE, Md. , Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment...

7 weeks ago - PRNewsWire

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit

ROCKVILLE, Md. , Jan. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. District Court for the District of Delaware granted Sarepta Therapeutics, Inc. (Sarepta) summary ju...

7 weeks ago - PRNewsWire

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial

First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal...

3 months ago - PRNewsWire

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Highest prior...

4 months ago - PRNewsWire

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. , Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Stifel 2023 Healthcare Conference  Fireside...

4 months ago - PRNewsWire

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2 prevented disease progression and reduced vis...

4 months ago - PRNewsWire

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m.

4 months ago - PRNewsWire

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

ROCKVILLE, Md. , Oct. 30, 2023 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, ...

4 months ago - PRNewsWire

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

ROCKVILLE, Md. , Oct. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023.

5 months ago - PRNewsWire

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be well-tolerated in three patients from dose...

5 months ago - PRNewsWire

REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

ROCKVILLE, Md. , Sept. 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in Charleston, SC from...

5 months ago - PRNewsWire

Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

Six-month data from single-patient, investigator-initiated trial showed that one-time administration of RGX-181 was well tolerated, achieved sustained gene expression and demonstrated clinically meani...

6 months ago - PRNewsWire

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

ROCKVILLE, Md. , Aug. 23, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 in Jerusale...

6 months ago - PRNewsWire

REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights

Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 ABBV-RGX-314 program ...

7 months ago - PRNewsWire

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday,...

7 months ago - PRNewsWire

REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights

ROCKVILLE, Md. , July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 2, 2023, at 4:30 p.m.

7 months ago - PRNewsWire

REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting

ROCKVILLE, Md. , July 24, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced three presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, taking ...

7 months ago - PRNewsWire